Molecular diagnosis of prostate cancer.
The diagnosis, staging, and management of prostate cancer as we know it today is greatly dependent on our ability to measure serum prostate-specific antigen (PSA) concentration. Nevertheless, because serum PSA concentration, particularly when less than 10 ng/mL, reflects the presence of benign prostatic hyperplasia more often than cancer, there is a clear need for more specific prostate cancer markers. The most promising new markers for prostate cancer are the various molecular forms of free PSA. Mass spectrometry also is emerging as a potential tool in prostate cancer screening. Because it is unlikely that any one marker will have 100% sensitivity and specificity, as new serum markers are tested, nomograms that incorporate multiple independently predictive parameters for the detection of prostate cancer will become indispensable in our efforts to improve prostate cancer screening.
Canto
Eduardo I
EI
Scott Department of Urology, Baylor College of Medicine, The Baylor Prostate Center, 6560 Fannin Street, Suite 2100, Houston, TX 77030, USA.
Shariat
Shahrokh F
SF
Slawin
Kevin M
KM
D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D008297:Male; D013058:Mass Spectrometry / Q000379:methods; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000737:chemistry; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis*; D020840:Tissue Kallikreins / Q000097:blood
D014408:Biomarkers, Tumor; D020840:Tissue Kallikreins; D017430:Prostate-Specific Antigen